Researchers found an estimated $165.2 million in savings in 2013 in Medicare spending on the prescription drugs that treat some of the same conditions that marijuana may be used to treat, according to the study. That was the same year that 17 states and the District of Columbia implemented medical marijuana laws.
The savings accounted for 0.5 percent of the 2013 budget of Medicare Part D (which is the part of the Medicare program that helps people pay for prescription drugs and drug insurance premiums). The researchers said that finding shows that people are turning to medical marijuana as an alternative to other medications. [11 Odd Facts About Marijuana]
"The results suggest people are really using marijuana as medicine and not just using it for recreational purposes," Ashley Bradford, a student researcher at the University of Georgia (UGA) and the lead author of the new study, said in a statement.
In the study, the researchers reviewed all claims for prescriptions filed between 2010 and 2013, by people enrolled in Medicare Part D, for the nine conditions that marijuana can be used to treat: anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity.
In particular, the researchers focused on prescriptions for treating glaucoma, they said.
"It turns out that glaucoma is one of the most Googled searches linked to marijuana, right after pain," study co-author W. David Bradford, a professor of public policy at UGA, said in the statement. And so, for this condition in particular, the researchers theorized that more people would have gone to the doctor as a result of demand for marijuana following the passage of medical marijuana laws.
However, when marijuana is used to treat glaucoma, the drug's effects last only an hour. And because using marijuana once an hour is unrealistic, the researchers expected that the wave of people going to the doctor for glaucoma would actually result in an increase in prescriptions for other glaucoma medications over the study period.
Indeed, the study showed that prescriptions for other glaucoma medications were higher in states that had medical marijuana laws in 2013 than in states that did not have legal medical marijuana. The states where marijuana was legal had, on average, 35 more doses of other glaucoma medications than the average of about 2,550 daily doses prescribed in states without a medical marijuana law.
But glaucoma medications were the exception. For the other conditions that marijuana can be used to treat, there were decreases in the number of prescriptions written for medications other than marijuana. For instance, prescriptions for drugs to treat pain were lower by 1,826 daily doses in the states where medical marijuana was legal compared with states where it was not legal (where the average was 31,810 daily doses).
Based on their results, the researchers estimated that the Medicare program would have saved about $468 million on prescription medications if all states had implemented medical marijuana.
In their study, the researchers noted that although their findings showed an association between the legalization of medical marijuana and Medicare savings, their study does not prove there is a cause-and-effect relationship.
Ashley Bradford said the study will continue, next by looking at medical marijuana's effects on Medicaid.
Bad news for Big Pharma
Anything that can steer people away from death-inducing prescription painkillers and other dangerous medications is a very positive step, no matter what your personal feelings are about marijuana. Of course, Big Pharma does not share this view, as it threatens their profits, which also explains why they are hoping people won't catch on to the benefits of CBD/CBDa oil from hemp for issues such as epilepsy.
Not only is marijuana very effective for many people, but it carries very few side effects, and is often more affordable than the pills Big Pharma is trying to push on people. This latest study showing that marijuana is replacing dangerous pharmaceuticals for many people might be bad news for Big Pharma, but it's good news for everybody else.
Original article on Live Science.
No comments:
Post a Comment